Cambrex is a global contract development and manufacturing organization (CDMO) focused on small‑molecule pharmaceuticals. The company provides drug substance services—covering active pharmaceutical ingredients (APIs) and intermediates—as well as drug product development and manufacturing, supporting programs from early development through commercial supply.
Operating cGMP facilities in North America and Europe, including a major site in Karlskoga, Sweden, Cambrex offers process and analytical development, scale‑up, and clinical and commercial manufacturing. Capabilities include high‑potency and controlled substances handling, continuous‑flow and high‑energy chemistry, solid oral dosage formulation, packaging, and stability services. The company serves innovator and generic pharmaceutical customers, working to international regulatory standards such as those of the FDA and EMA.